About Erasca
Erasca is a company based in San Diego (United States) founded in 2018.. Erasca has raised $300 million across 5 funding rounds from investors including Orbimed, Arch Venture Partners and TMCP. The company has 103 employees as of December 31, 2024. Erasca offers products and services including MAPKlamp and RAS Targeting Therapies. Erasca operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 103 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Erasca, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-161.65 M-29.28as on Dec 31, 2024
-
EBITDA
$-148.63 M-7.86as on Dec 31, 2024
-
Total Equity Funding
$300 M (USD)
in 5 rounds
-
Latest Funding Round
$45 M (USD), Post-IPO
Mar 27, 2024
-
Investors
Orbimed
& 11 more
-
Employee Count
103
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Erasca
Erasca is a publicly listed company on the NASDAQ with ticker symbol ERAS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Erasca
Erasca offers a comprehensive portfolio of products and services, including MAPKlamp and RAS Targeting Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets MAPK pathway nodes for cancer treatment
Directly inhibits RAS mutations in cancer signaling
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Senior Team
10 people
Finance and Accounting
7 people
Product Management Team
5 people
Operations Team
4 people
Legal and Compliance
2 people
Data Analysis and Operations Team
2 people
Human Resources and Administration
2 people
Unlock access to complete
Funding Insights of Erasca
Erasca has successfully raised a total of $300M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $45 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $45.0M
-
First Round
First Round
(18 Dec 2018)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Post-IPO - Erasca | Valuation |
investors |
|
| Aug, 2020 | Amount | Series B - Erasca | Valuation | Orbimed , PFM Health Sciences |
|
| Apr, 2020 | Amount | Series B - Erasca | Valuation | Arch Venture Partners , Cormorant Asset Management |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Erasca
Erasca has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Arch Venture Partners and TMCP. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Private equity investments in China are managed by TMCP.
|
Founded Year | Domain | Location | |
|
Venture capital firm and foundation focused on biotech, cleantech, and media & entertainment, education, and more
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Erasca
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Erasca
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Erasca Comparisons
Competitors of Erasca
Erasca operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Erasca
Frequently Asked Questions about Erasca
When was Erasca founded?
Erasca was founded in 2018.
Where is Erasca located?
Erasca is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Erasca a funded company?
Erasca is a funded company, having raised a total of $300M across 5 funding rounds to date. The company's 1st funding round was a Series B of $200M, raised on Dec 18, 2018.
How many employees does Erasca have?
As of Dec 31, 2024, the latest employee count at Erasca is 103.
What does Erasca do?
Erasca was founded in 2018 in San Diego, United States, within the biotechnology sector. Small molecule-based therapeutics are developed by the company to address oncology needs. Product candidates including naporafenib, ERAS-007, and ERAS-80 are advanced for melanoma and tissue-agnostic solid tumors. Operations focus on drug discovery and clinical development in the United States.
Who are the top competitors of Erasca?
Erasca's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
What products or services does Erasca offer?
Erasca offers MAPKlamp and RAS Targeting Therapies.
Is Erasca publicly traded?
Yes, Erasca is publicly traded on NASDAQ under the ticker symbol ERAS.
Who are Erasca's investors?
Erasca has 12 investors. Key investors include Orbimed, Arch Venture Partners, TMCP, City Hill, and Colt Ventures.
What is Erasca's ticker symbol?
The ticker symbol of Erasca is ERAS on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.